| Date | Title | Description | |
|---|---|---|---|
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
| 09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 16 Jun 2022 | Other relevant information | The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs | Download |
| 14 Jun 2022 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 11 May 2022 | On business and financial situation | The Company releases the press release related to the first quarter 2022 financial result | Download |
| 11 May 2022 | On business and financial situation | The Company releases the first quarter 2022 financial results presentation | Download |
| 11 May 2022 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2022 General Shareholders Meeting | Download |